• Amplia entered a clinical trial collaboration and supply agreement with Eli Lilly to test narmafotinib with olomorasib in advanced NSCLC.
• Phase 1b/2b study targets second-line patients; trial start planned for late 2026 at sites in Australia and the U.S.
• Lilly will provide in-kind supply of olomorasib; Amplia will run the trial.
• Deal expands narmafotinib development beyond pancreatic cancer into NSCLC; company cited a NSCLC market of about USD 31 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amplia Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608040845PRIMZONEFULLFEED9802953) on August 04, 2026, and is solely responsible for the information contained therein.